Phase 1
Completed N=13
The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)
Source: ClinicalTrials.gov NCT00943852 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Jul 2010
Primary outcomePrimary: Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg — -24.9; -1.8 Percent Change — p=<0.001
Summary
This study will qualify a functional model that can measure central blood pressure and vascular compliance effects through noninvasive means.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg |
-24.9; -1.8 | <0.001 sig |
| PRIMARY Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo |
-24.9; -1.3 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Patient is in good health with the exception of mild to moderate hypertension
- Patient is willing to comply with the study restrictions
- Patient does not smoke
Exclusion Criteria
- Patient has a history of any illness that might confound the results of the study or make participation in the study unsafe
- Patient is taking a prescription medication that is contraindicated for use with COZAAR® or IMDUR®
- Patient has a condition for which there is a warning, contraindication, or precaution against the use of COZAAR® or IMDUR®
Data sourced from ClinicalTrials.gov (NCT00943852). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.